Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: Lower toxicity with suitable premedication

Mycoses

Volumn 50, Issue 2, 2007, Pages 135-139

  Oto, Ozgur Akin ^a   Paydas, Semra ^a   Disel, Umut ^a   Yavuz, Sinan ^a   Seydaoglu, Gulsah ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Amphotericin B deoxycholate; Fungal infections; Neutropenia; Suitable premedication; Toxicity

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B DEOXYCHOLATE; ANTIHISTAMINIC AGENT; CARBAPENEM; CEPHALOSPORIN; CORTICOSTEROID; CREATININE; GLYCOPEPTIDE; MAGNESIUM; POTASSIUM;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYANOSIS; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AMPHOTERICIN B; CREATININE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; KIDNEY; MAGNESIUM; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; POTASSIUM; RETROSPECTIVE STUDIES; UREA;

EID: 33846973373     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01337.x     Document Type: Article

References (20)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
2. Walsh TJ, Pizzo PA. Nosocomial fungal infections: a classification for hospitalacquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol 1988; 42: 517-45.
3. Seabury JH, Dascomb HE. Experience with amphotericin B. Ann NY Acad Sci 1960; 89: 200-20.
4. Flückiger U. Is 24 hours infusion of amphotericin B deoxycholate as good as liposomal amphotericin B. Swiss Med Wkly 2002; 132: 431-2.
5. Butler WT, Hill GJ, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. J Pharmacol Exp Ther 1964; 143: 47-56.
6. Stevens DA, Bennet JE. Antifungal Agents. In: Mandell GL (ed.), Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000: 448-59.
7. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia (Cochrane review). In: Cochrane Database Syst Rev. 2000; 3: CD000969.
8. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future direction. Clin Infect Dis 1996; 22 (Suppl. 2): S133-44
9. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss Med Wkly 2002; 132: 316-20.
10. Peacock JE, Herrington DA, Cruz JM. Amphotericin B therapy: past, present, and future. Infect Dis Clin Pract 1993; 2: 81-93.
11. Ural AU. Spironolactone prevents amphotericin B-induced hypokalemia in neutropenic patients: Comment. Ann Pharmacother 2000; 34: 1488.
12. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999; 7: 51-6.
13. Fisher MA, Talbot GH, Maislin G, M Strom BL. Risk factors for Amphothericin B-associated nephrotoxicity. Am J Med 1989; 87: 547-52.
14. Erikkson U, Seifert B, Schaffner A. Comparison of effects of amphtotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 10: 579-82.
15. Heidemann HT, Gerkens GF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in human decreased by salt repletion. Am J Med 1983; 75: 476-81.
16. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. JID 2002; 186: 379-88.
17. Walsh TJ, Finberg RW, Arndt C. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
18. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11: 187-290.
19. Girmenia C, Cimino G, Di Cristofano F, Micozzi A, Gentile G, Martino P. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Support Care Cancer 2005; 13: 987-92.
20. Wright DG, Robichaud KJ, Pizzo PA et al. Lethal pulmonary reactions associated with combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185.